Indication
Prevention of Mycobacterium avium complex disease
The prevention of *Mycobacterium avium* complex disease is a prophylactic clinical strategy targeted primarily at severely immunocompromised individuals, most notably patients with advanced human immunodeficiency virus infection presenting with CD4 T-lymphocyte counts below 50 cells/µL. Read more about Prevention of Mycobacterium avium complex disease
32 drugs 30 manufacturers
Drugs that treat it
Common Prevention of Mycobacterium avium complex disease therapies.
RIFABUTIN
CLARITHROMYCIN
CLARITHROMYCIN
RIFABUTIN
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonThe prevention of *Mycobacterium avium* complex disease is a prophylactic clinical strategy targeted primarily at severely immunocompromised individuals, most notably patients with advanced human immunodeficiency virus infection presenting with CD4 T-lymphocyte counts below 50 cells/µL.
*Mycobacterium avium* complex comprises environmental nontuberculous mycobacteria—principally *M.
avium* and *M.
intracellulare*—that can colonize the respiratory or gastrointestinal tracts.
In profound immunosuppression, impaired cell-mediated immunity permits hematogenous dissemination of the bacilli across multiple organ systems, resulting in severe systemic manifestations such as debilitating fevers, night sweats, profound weight loss, severe anemia, hepatosplenomegaly, and bacteremia.
Prophylactic therapy aims to forestall this life-threatening disseminated bacteremic infection before it becomes established.
- cdc.gov
The prevention of *Mycobacterium avium* complex disease is a prophylactic clinical strategy targeted primarily at severely immunocompromised individuals, most notably patients with advanced human immunodeficiency virus infection presenting with CD4 T-lymphocyte counts below 50 cells/µL In profound immunosuppression, impaired cell-mediated immunity permits hematogenous dissemination of the bacilli across multiple organ systems, resulting in severe systemic manifestations such as debilitating feve...
- aidsetc.org
The prevention of *Mycobacterium avium* complex disease is a prophylactic clinical strategy targeted primarily at severely immunocompromised individuals, most notably patients with advanced human immunodeficiency virus infection presenting with CD4 T-lymphocyte counts below 50 cells/µL
- nih.gov
*Mycobacterium avium* complex comprises environmental nontuberculous mycobacteria—principally *M. avium* and *M. intracellulare*—that can colonize the respiratory or gastrointestinal tracts
- iapac.org
*Mycobacterium avium* complex comprises environmental nontuberculous mycobacteria—principally *M. avium* and *M. intracellulare*—that can colonize the respiratory or gastrointestinal tracts
- hiv.gov
In profound immunosuppression, impaired cell-mediated immunity permits hematogenous dissemination of the bacilli across multiple organ systems, resulting in severe systemic manifestations such as debilitating fevers, night sweats, profound weight loss, severe anemia, hepatosplenomegaly, and bacteremia
- uw.edu
In profound immunosuppression, impaired cell-mediated immunity permits hematogenous dissemination of the bacilli across multiple organ systems, resulting in severe systemic manifestations such as debilitating fevers, night sweats, profound weight loss, severe anemia, hepatosplenomegaly, and bacteremia
Personalize your experience
Follow Prevention of Mycobacterium avium complex disease and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.